Abata Therapeutics
Regulatory T cell therapies for autoimmune diseases
- Sector
- Biotech
- Headquarters
- WATERTOWN, MA
- Founded
- 2020
- Latest Form D
- $15.3M, Dec 2023
- Total capital
- $60.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $60.3M
- 2 Form D · last Dec 2023
- 34 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 30 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$15.3M
- Private capital raisedForm D · SEC · 1st filing$45M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- ABBIE CELNIKERExecutive Officer, DirectorNamed in SEC Form D filings
- DAVID KAUFMANDirectorNamed in SEC Form D filings
- ELLEN CAHIR-MCFARLANDExecutive OfficerNamed in SEC Form D filings
- JOHN TRZUPEKExecutive OfficerNamed in SEC Form D filings
- LEONARD DRAGONEExecutive OfficerNamed in SEC Form D filings
- LORENCE KIMDirectorNamed in SEC Form D filings
Show all 13 people
- MITCH FINERDirectorNamed in SEC Form D filings
- NAGESH MAHANTHAPPADirectorNamed in SEC Form D filings
- SAMANTHA SINGERExecutive Officer, DirectorNamed in SEC Form D filings
- SANDY LAZZARIExecutive OfficerNamed in SEC Form D filings
- SHELLEY CHUDirectorNamed in SEC Form D filings
- STEPHEN SOFENExecutive OfficerNamed in SEC Form D filings
- VALERIE ODEGARDDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 30- PendingCell Therapies For Multiple SclerosisUSPTOApplication 19050528
- PendingCell Therapies For Type 1 DiabetesUSPTOApplication 19229739
- PendingRegulatory T Cell Stability AssayUSPTOApplication 19181950
Show all 30 patent records
- Cell Therapies For Multiple SclerosisFeb 5, 2026 · Application 19050528Pending
- Cell Therapies For Type 1 DiabetesSep 25, 2025 · Application 19229739Pending
- Regulatory T Cell Stability AssayAug 14, 2025 · Application 19181950Pending
- Stable Regulatory T Cells And Methods Of ProductionJun 12, 2025 · Application 19050510Pending
- Cell Therapies For Type 1 DiabetesApplication PCTUS2024025443Pending
- Patient Selection And Treatment For Multiple SclerosisApplication 63552941Pending
- Cell Therapies For Type 1 DiabetesApplication 63614065Pending
- Cell Therapies For Type 1 DiabetesApplication PCTUS2023084859Pending
- Regulatory T Cell Stability AssayApplication PCTUS2023077260Pending
- Cell Therapies For Type 1 DiabetesApplication 63578226Pending
- Cell Therapies For Multiple SclerosisApplication PCTUS2023072049Pending
- Stable Regulatory T Cells And Methods Of ProductionApplication PCTUS2023072045Pending
- Cell Therapies For Type 1 DiabetesApplication 63461003Pending
- Cell Therapies For Type 1 DiabetesApplication 63459843Pending
- Cell Therapies For Type 1 DiabetesApplication 63434062Pending
- Regulatory T Cell Stability AssayApplication 63432136Pending
- Hybrid T Cell Receptors Targeting Myelin Basic ProteinApplication 63432304Pending
- Regulatory T Cell Stability AssayApplication 63417474Pending
- Cell Therapies For Multiple SclerosisApplication 63417465Pending
- Stable Regulatory T Cells And Methods Of ProductionApplication 63417422Pending
- Cell Therapies For Multiple SclerosisApplication 63415362Pending
- Stable Regulatory T Cells And Methods Of ProductionApplication 63412032Pending
- Cell Therapies For Multiple SclerosisApplication 63412142Pending
- Stable Regulatory T Cells And Methods Of ProductionApplication 63397704Pending
- Cell Therapies For Multiple SclerosisApplication 63397715Pending
- Cell Therapies For Type 1 DiabetesApplication 19477373Pending
- Cell Therapies For Type 1 DiabetesApplication 19600315Pending
- Patient Selection And Treatment For Multiple SclerosisApplication PCTUS2025015584Pending
- Cell Therapies For Type 1 DiabetesApplication PCTUS2024061312Pending
- Patient Selection And Treatment For Multiple SclerosisApplication 63685474Pending
Related companies, and why
- Liminal BioSciences Inc.Similar federal contract value in Biotech · null in contracts
- Ernexa Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- KAZIA THERAPEUTICS LTDSimilar federal contract value in Biotech · null in contracts
- Ankyra Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Checkpoint Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Longboard Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .